Outcome of multiple regression analyses with VWF, LDH, and free heme as dependent variables
| Outcomes of mediation analysis . | ||
|---|---|---|
| Outcome: VWF . | B (95% CI) . | P value . |
| Age | 0.5 (−1.1 to 2.0) | .552 |
| Blood group (non-O) | 30.2 (17.3-43.2) | <.001 |
| Treatment (BT) | −17.0 (−29.7 to −4.3) | .009 |
| HbS is independently associated with VWF | ||
| Age | 0.1 (−1.4 to 1.7) | .854 |
| Blood group (non-O) | 29.6 (16.6-42.5) | <.001 |
| HbS | 0.3 (0.1-0.6) | .003 |
| Treatment and HbS nullify each other’s effects | ||
| Age | 0.1 (−1.4 to 1.7) | .877 |
| Blood group (non-O) | 29.5 (16.4-42.5) | <.001 |
| Treatment (BT) | 4.2 (−27.2 to −35.7) | .791 |
| HbS | 0.4 (−0.1 to 1.0) | .143 |
| LDH and free heme are independently associated with VWF | ||
| Age | 0.9 (−1.7 to 3.6) | .483 |
| Blood group (non-O) | 47.1 (27.9-66.3) | <.001 |
| Treatment (BT) | −24.2 (−43.2 to −5.3) | .013 |
| LDH (×10−2) | 3.2 (0.4-6.0) | .027 |
| Free heme | −1.0 (−2.0 to 0.0) | .045 |
| Addition of angiopoietin-2 nullifies the effect of treatment, LDH, and free heme | ||
| Age | 0.5 (−2.9 to 3.9) | .766 |
| Blood group (non-O) | 39.6 (13.9-65.3) | .003 |
| Treatment (BT) | −24.2 (−50.1 to 1.7) | .067 |
| LDH (×10−2) | 0.5 (−3.3 to 4.2) | .807 |
| Free heme | −0.9 (−2.7 to 0.9) | .311 |
| Angiopoietin-2 (×10−3) | 6.3 (0.2-12.4) | .043 |
| HbS and VWF are independently associated with LDH | ||
| Outcome: LDH | ||
| HbS | 1.8 (0.1-3.5) | .044 |
| VWF | 1.9 (0.8-3.0) | .001 |
| LDH is independently associated with free heme | ||
| Outcome: free heme | ||
| Treatment | −2.2 (−11.1 to 6.9) | .636 |
| HbS | 0.0 (−0.2 to 0.1) | .909 |
| LDH | 0.5 (0.1-1.0) | .022 |
| Outcomes of mediation analysis . | ||
|---|---|---|
| Outcome: VWF . | B (95% CI) . | P value . |
| Age | 0.5 (−1.1 to 2.0) | .552 |
| Blood group (non-O) | 30.2 (17.3-43.2) | <.001 |
| Treatment (BT) | −17.0 (−29.7 to −4.3) | .009 |
| HbS is independently associated with VWF | ||
| Age | 0.1 (−1.4 to 1.7) | .854 |
| Blood group (non-O) | 29.6 (16.6-42.5) | <.001 |
| HbS | 0.3 (0.1-0.6) | .003 |
| Treatment and HbS nullify each other’s effects | ||
| Age | 0.1 (−1.4 to 1.7) | .877 |
| Blood group (non-O) | 29.5 (16.4-42.5) | <.001 |
| Treatment (BT) | 4.2 (−27.2 to −35.7) | .791 |
| HbS | 0.4 (−0.1 to 1.0) | .143 |
| LDH and free heme are independently associated with VWF | ||
| Age | 0.9 (−1.7 to 3.6) | .483 |
| Blood group (non-O) | 47.1 (27.9-66.3) | <.001 |
| Treatment (BT) | −24.2 (−43.2 to −5.3) | .013 |
| LDH (×10−2) | 3.2 (0.4-6.0) | .027 |
| Free heme | −1.0 (−2.0 to 0.0) | .045 |
| Addition of angiopoietin-2 nullifies the effect of treatment, LDH, and free heme | ||
| Age | 0.5 (−2.9 to 3.9) | .766 |
| Blood group (non-O) | 39.6 (13.9-65.3) | .003 |
| Treatment (BT) | −24.2 (−50.1 to 1.7) | .067 |
| LDH (×10−2) | 0.5 (−3.3 to 4.2) | .807 |
| Free heme | −0.9 (−2.7 to 0.9) | .311 |
| Angiopoietin-2 (×10−3) | 6.3 (0.2-12.4) | .043 |
| HbS and VWF are independently associated with LDH | ||
| Outcome: LDH | ||
| HbS | 1.8 (0.1-3.5) | .044 |
| VWF | 1.9 (0.8-3.0) | .001 |
| LDH is independently associated with free heme | ||
| Outcome: free heme | ||
| Treatment | −2.2 (−11.1 to 6.9) | .636 |
| HbS | 0.0 (−0.2 to 0.1) | .909 |
| LDH | 0.5 (0.1-1.0) | .022 |
CI, confidence interval.